Iright
BRAND / VENDOR: CST

CST, 3710S, Phospho-ALK (Tyr1278) Antibody

CATALOG NUMBER: 3710S
Regular price$0.99
/
Shipping calculated at checkout.
  • ddddd

    99 xxxxxx

  • Backordered, shipping soon

This site is protected by hCaptcha and the hCaptcha Privacy Policy and Terms of Service apply.

Product Description
Polyclonal Antibody for studying ALK (Tyr1278) phosphate. Validated for Western Blotting. Highly specific and rigorously validated in-house, Phospho-ALK (Tyr1278) Antibody (CST #3710) is ready to ship. Product Usage Information Western Blotting: 1:1000 Storage Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA and 50% glycerol. Store at -20°C. Do not aliquot the antibody. Protocol Available protocols: Western Blotting Specificity / Sensitivity Phospho-ALK (Tyr1278) Antibody detects ALK only when phosphorylated at Tyr1278, which is equivalent to Tyr338 of NPM-ALK. This antibody also reacts with leukocyte tyrosine kinase (LTK) phosphorylated at Tyr672, and may cross-react with other activated protein tyrosine kinases including Bcr-Abl. Species Reactivity: Human Source / Purification Polyclonal antibodies are produced by immunizing animals with a synthetic phosphopeptide corresponding to residues surrounding Tyr1278 of human ALK. Antibodies are purified by protein A and peptide affinity chromatography. Background Anaplastic lymphoma kinase (ALK) is a tyrosine kinase receptor for pleiotrophin (PTN), a growth factor involved in embryonic brain development (1-3). In ALK-expressing cells, PTN induces phosphorylation of both ALK and the downstream effectors IRS-1, Shc, PLCγ, and PI3 kinase (1). ALK was originally discovered as a nucleophosmin (NPM)-ALK fusion protein produced by a translocation (4). Investigators have found that the NPM-ALK fusion protein is a constitutively active, oncogenic tyrosine kinase associated with anaplastic lymphoma (4). Research literature suggests that activation of PLCγ by NPM-ALK may be a crucial step for its mitogenic activity and involved in the pathogenesis of anaplastic lymphomas (5). A distinct ALK oncogenic fusion protein involving ALK and echinoderm microtubule-associated protein like 4 (EML4) has been described in the research literature from a non-small cell lung cancer (NSCLC) cell line, with corresponding fusion transcripts present in some cases of lung adenocarcinoma. The short, amino-terminal region of the microtubule-associated protein EML4 is fused to the kinase domain of ALK (6-8). Phosphorylation of ALK on Tyr1278 was identified at Cell Signaling Technology (CST) using PhosphoScan , CST's LC-MS/MS platform for phosphorylation site discovery. Phosphorylation of ALK at Tyr1278 was observed in select carcinoma cell lines and in tumors (6). Alternate Names ALK; ALK receptor tyrosine kinase; ALK tyrosine kinase receptor; Anaplastic lymphoma kinase; anaplastic lymphoma receptor tyrosine kinase; CD246; CD246 antigen; mutant anaplastic lymphoma kinase; NBLST3 Specification REACTIVITY: H SENSITIVITY: Endogenous MW (kDa): 220 (ALK), 80 (NPM-ALK) SOURCE: Rabbit

Order Guidelines

1. Price & Stock Available on Request. 📧Click to send email to: service@iright.com

2. Please DO NOT make payment before confirmation.

3. Minimum order value of $1,000 USD required.

Collaboration

Tony Tang

📧Email: Tony.Tang@iright.com

📱Mobile/WhatsApp/Wechat: +86-17717886924